ABA Autism denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for aba autism are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies ABA Therapy as Experimental

An "experimental" or "investigational" denial for Applied Behavior Analysis therapy in autism spectrum disorder is one of the most legally and clinically contested denial types in behavioral health coverage. ABA has been studied extensively over decades and is endorsed as an evidence-based intervention by major medical and scientific organizations, including the U.S. Surgeon General and the American Academy of Pediatrics. Aetna's clinical policy on ABA has evolved significantly over time, and if you have received this denial recently, it may reflect an outdated review, a miscategorized claim, or a plan-specific exclusion that conflicts with state autism insurance mandates.

## Why This Is Appealable

Forty-plus states have autism insurance mandate laws that explicitly require coverage of ABA therapy and prohibit characterizing it as experimental. If your plan is a fully-insured plan in a state with an autism mandate, Aetna may not lawfully apply an experimental exclusion to ABA. Self-funded ERISA plans are exempt from state mandates but are still subject to MHPAEA, which requires that experimental-treatment criteria applied to behavioral health services be no more restrictive than those applied to analogous medical services. ACA §2719 and ERISA §503 provide internal appeal and external review rights (4-month window after final internal denial).

## Documentation to Gather

• Diagnosis confirmation: A formal ASD diagnosis from a licensed psychologist, developmental pediatrician, or psychiatrist, including the diagnostic instrument used and the date of evaluation.
• State mandate research: Confirm whether your state has an autism insurance mandate and whether your plan is fully insured (state mandate applies) or self-funded (state mandate does not apply, but MHPAEA does).
• Medical-necessity and evidence letter: A letter from the treating BCBA or physician summarizing the evidence base for ABA as recognized by the American Academy of Pediatrics, the U.S. Surgeon General's report, and other recognized bodies — without citing specific statistics — and confirming that the prescribed treatment follows established professional standards.
• Current treatment plan: The individualized ABA treatment plan with specific behavioral goals.
• MHPAEA parity argument: Document any Aetna medical services that are covered despite having a comparable or thinner evidence base, to support a parity challenge.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy bulletin for ABA/autism. Identify the exact language Aetna used to classify ABA as experimental. In your appeal, address each element of that classification with citations to recognized professional bodies (by name, not by statistic) and the applicable state or federal legal standard.

## Timeline

1. File internal appeal within 180 days of denial. 2. For a child whose treatment has been interrupted: request expedited review (72 hours). 3. After final internal denial: request external review within 4 months. 4. If state mandate violation is suspected: file a concurrent complaint with your state insurance commissioner.